Non-alcoholic fatty liver disease in 2016

Sarah Townsend, Philip N Newsome

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)
415 Downloads (Pure)


INTRODUCTION: Non-alcoholic fatty liver disease is the commonest cause of liver disease worldwide, and is rapidly becoming the leading indication for liver transplantation.

SOURCES OF DATA: Original articles, reviews and meta-analyses, guidelines.

AREAS OF AGREEMENT: NAFLD strongly correlates with obesity and insulin resistance; currently, the best management strategy is weight loss and treatment of the metabolic syndrome.

AREAS OF CONTROVERSY: Recent data suggest that the presence of fibrosis and not non-alcoholic steatohepatitis (NASH) is the predictor of clinical outcome.

GROWING POINTS: Many phase 2 and 3 trials are underway. Drugs hoped to be effective are obeticholic acid, elafibranor, glucagon-like peptide-1 analogues and CCR2/5 inhibitors.

AREAS TIMELY FOR DEVELOPING RESEARCH: Improved understanding of the pathophysiology of NAFLD should help us identify which patients progress to significant liver disease and to develop therapies to target this population.

Original languageEnglish
Pages (from-to)143-56
Number of pages14
JournalBritish Medical Bulletin
Issue number1
Early online date19 Aug 2016
Publication statusPublished - Sept 2016


Dive into the research topics of 'Non-alcoholic fatty liver disease in 2016'. Together they form a unique fingerprint.

Cite this